Expertise in
12
conditions

Dr. Kathleen M. Mullane

Internal Medicine
University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
12
conditions
University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 

Overview

Kathleen Mullane is a primary care provider, practicing in Internal Medicine in Chicago, Illinois.

Dr. Mullane is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Pseudomembranous Colitis, Shingles, Cytomegalovirus Infection, and Aspergillosis.

She is actively involved in clinical research, co-authoring 61 peer reviewed articles and participating in 8 clinical trials. Dr. Mullane is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

University of Chicago Medical Center
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
Enrollment Status: Recruiting
Publish Date: June 23, 2026
Intervention Type: Drug
Study Drug: DAS181
Study Phase: Phase 3
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Drug: Ibrexafungerp
Study Phase: Phase 3
Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)
Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study)
Enrollment Status: Terminated
Publish Date: November 08, 2024
Intervention Type: Drug, Other
Study Phase: Phase 1
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus in High-risk Pediatric Allogeneic Hematopoietic Transplant Recipients
Enrollment Status: Terminated
Publish Date: January 25, 2021
Intervention Type: Other, Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 7 Less Clinical Trials

61 Total Publications

Expect the unexpected: endocarditis caused by Legionella feeleii.
Expect the unexpected: endocarditis caused by Legionella feeleii.
Journal: Laboratory medicine
Published: May 23, 2024
Similar Doctors
Expertise in
8
conditions
Dr. Robert E. Molokie
Internal Medicine
Expertise in
8
conditions
Dr. Robert E. Molokie
Internal Medicine

University Of Illinois Hospital

1740 W Taylor St, 
Chicago, IL 
 (6.5 miles away)
312-413-8666
Languages Spoken:
English
See accepted insurances

Robert Molokie is a primary care provider, practicing in Internal Medicine in Chicago, Illinois. Dr. Molokie is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy.

Expertise in
13
conditions
Dr. Eric S. Chung
Internal Medicine
Expertise in
13
conditions
Dr. Eric S. Chung
Internal Medicine
1776 N Milwaukee Ave, 
Chicago, IL 
 (9.5 miles away)
708-923-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Chung is a primary care provider, practicing in Internal Medicine in Chicago, Illinois. Dr. Chung is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Peyronie Disease, Erectile Dysfunction (ED), Urinary Incontinence, Prostatectomy, and Prostatic Artery Embolization. Dr. Chung is board certified in American Board Of Internal Medicine - Internal Medicine (Certified). Dr. Chung is currently accepting new patients.

Expertise in
2
conditions
Dr. Margarite D. Matossian
Internal Medicine
Expertise in
2
conditions
Dr. Margarite D. Matossian
Internal Medicine

University Of Chicago Hospitals

5758 S Maryland Ave, 
Chicago, IL 
 (0.1 miles away)
773-795-0232
Languages Spoken:
English
See accepted insurances

Margarite Matossian is a primary care provider, practicing in Internal Medicine in Chicago, Illinois. Dr. Matossian is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, and Hereditary Spherocytosis.

Frequently Asked Questions about Dr. Kathleen M. Mullane

How do I make an appointment with Dr. Kathleen M. Mullane?

You can book an appointment with Dr. Kathleen M. Mullane by calling their office at 773-702-6119. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kathleen M. Mullane a top-rated expert for Pseudomembranous Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kathleen M. Mullane is classified as an Distinguished expert for Pseudomembranous Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kathleen M. Mullane specialize in?

While Dr. Kathleen M. Mullane is a Internal Medicine, they have specific expertise in Pseudomembranous Colitis, Shingles, and Cytomegalovirus Infection. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Kathleen M. Mullane participate in research or clinical trials?

Yes. Dr. Kathleen M. Mullane has published 61 articles and abstracts on conditions like Pseudomembranous Colitis. You can view a list of Dr. Kathleen M. Mullane's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kathleen M. Mullane accept my insurance?

Dr. Kathleen M. Mullane accepts most major insurance plans, including Anthem BCBS and Cigna. We recommend calling the office directly at 773-702-6119 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mullane's expertise for a condition
ConditionClose
    View All 10 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile